Pharmaceutical Report Library l Report Store l Pharma Intelligence

Adcirca

Launching after Revatio, Adcirca became the second-to-market PDE5 inhibitor upon its approval in major markets in 2009. Inhibiting the PDE5 enzyme enhances the effect of the endogenous vasodilator, nitric oxide (NO).

October 29, 2018

Find out more

Bone Grafts and Substitutes

$4,750.00

This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global market for bone grafts and substitutes. Product segments covered by this report include allografts and synthetic bone substitutes, growth factors, and cellular bone matrices.

February 15, 2022

Find out more

Ultibro

Ultibro’s (indacaterol/glycopyrrolate bromide; Novartis/Pfizer) extensive clinical trial program for

chronic obstructive pulmonary disease (COPD) and its first-in-class status in Japan and select EU

markets boost its overall clinical and commercial attractiveness.

April 11, 2016

Find out more

Disease Analysis: Psoriasis

First-line treatment of milder forms of psoriasis will continue to be with cheaper, topical medications. Use of more expensive, systemic therapies will continue to be relegated to more severe psoriasis.

June 27, 2022

Find out more

N8-GP

N8-GP is a glycoPEGylated long-acting recombinant factor VIII (rfVIII) therapy under development by Novo Nordisk for the treatment of hemophilia A.

May 4, 2018

Find out more

Zoladex

Zoladex (goserelin; AstraZeneca/TerSera Therapeutics) is a gonadotropin-releasing hormone (GnRH) receptor agonist which acts on the pituitary gland to stimulate luteinizing hormone (LH) release, resulting in a temporary surge in serum testosterone levels known as “flare.”

January 18, 2018

Find out more

Innovation in Deal-Making

$3,000.00

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.

June 13, 2018

Find out more

MOR208

MorphoSys is positioning its cluster of differentiation (CD)19-targeted monoclonal antibody MOR208 in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant.

October 9, 2018

Find out more

Disease Analysis: COVID-19 Prevention

COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.

May 17, 2022

Find out more

Trulicity

Trulicity (dulaglutide; Eli Lilly) is approved for the treatment of type 2 diabetes. It is a sustained-release formulation glucagon-like peptide-1 (GLP-1) agonist and therefore acts on the incretin system.

November 7, 2017

Find out more

Idelvion

Idelvion is a long-acting recombinant factor IX (rfIX) therapy developed by CSL Behring for hemophilia B. Idelvion is produced through the fusion of rfIX, manufactured in Chinese hamster ovary cells, to human recombinant albumin via a cleavable linker.

May 4, 2018

Find out more

Xultophy

Xultophy ([insulin degludec + liraglutide]; Novo Nordisk) is a once-daily, injectable combination product comprising a fixed ratio of Novo Nordisk’s long-lasting basal insulin Tresiba (insulin degludec) and glucagon-like peptide-1 receptor agonist Victoza (liraglutide) for the treatment of type 2 diabetes.

November 7, 2017

Find out more

Drug Delivery: Infusion Devices – August 2020

$4,750.00

This report provides a discussion of current/forecast markets, competitors, and opportunities in the global infusion drug delivery devices market, including the volumetric, syringe, ambulatory, disposable, implantable, and enteral pumps segments. Geographic regions covered include the US, five major European markets, Japan, and Rest of World markets; the forecast period is from 2019–24.

August 14, 2020

Find out more

Market Spotlight: Primary Sclerosing Cholangitis (PSC)

$1,318.00

This Market Spotlight report covers the Primary Sclerosing Cholangitis (PSC) market, comprising key pipeline drugs, recent events and analyst opinion, upcoming events, clinical trials, probability of success, licensing and asset acquisition deals, and a 10-year disease prevalence forecast.

May 25, 2022

Find out more

abexinostat

Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone.

March 6, 2019

Find out more

Report library

Adcirca

Bone Grafts and Substitutes

Ultibro

Disease Analysis: Psoriasis

N8-GP

Zoladex

Innovation in Deal-Making

MOR208

Disease Analysis: COVID-19 Prevention

Trulicity

Idelvion

Xultophy

Drug Delivery: Infusion Devices – August 2020

Market Spotlight: Primary Sclerosing Cholangitis (PSC)

abexinostat